Aldeyra Therapeutics (ALDX) Competitors $4.80 +0.28 (+6.19%) Closing price 04:00 PM EasternExtended Trading$4.85 +0.05 (+1.13%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALDX vs. AVDL, ARDX, XERS, CRON, USNA, XNCR, KALV, RLAY, RGLS, and AMLXShould you be buying Aldeyra Therapeutics stock or one of its competitors? The main competitors of Aldeyra Therapeutics include Avadel Pharmaceuticals (AVDL), Ardelyx (ARDX), Xeris Biopharma (XERS), Cronos Group (CRON), USANA Health Sciences (USNA), Xencor (XNCR), KalVista Pharmaceuticals (KALV), Relay Therapeutics (RLAY), Regulus Therapeutics (RGLS), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "med - drugs" industry. Aldeyra Therapeutics vs. Its Competitors Avadel Pharmaceuticals Ardelyx Xeris Biopharma Cronos Group USANA Health Sciences Xencor KalVista Pharmaceuticals Relay Therapeutics Regulus Therapeutics Amylyx Pharmaceuticals Avadel Pharmaceuticals (NASDAQ:AVDL) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends. Which has more risk & volatility, AVDL or ALDX? Avadel Pharmaceuticals has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Do institutionals & insiders believe in AVDL or ALDX? 69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 5.2% of Avadel Pharmaceuticals shares are owned by insiders. Comparatively, 9.6% of Aldeyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has better earnings & valuation, AVDL or ALDX? Avadel Pharmaceuticals has higher revenue and earnings than Aldeyra Therapeutics. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvadel Pharmaceuticals$169.12M5.59-$48.83M-$0.27-36.19Aldeyra TherapeuticsN/AN/A-$55.85M-$0.97-4.95 Is AVDL or ALDX more profitable? Aldeyra Therapeutics has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -13.58%. Avadel Pharmaceuticals' return on equity of -36.07% beat Aldeyra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avadel Pharmaceuticals-13.58% -36.07% -16.30% Aldeyra Therapeutics N/A -72.58%-52.32% Do analysts prefer AVDL or ALDX? Avadel Pharmaceuticals presently has a consensus target price of $18.17, indicating a potential upside of 85.94%. Aldeyra Therapeutics has a consensus target price of $9.50, indicating a potential upside of 97.92%. Given Aldeyra Therapeutics' higher probable upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Avadel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avadel Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Aldeyra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to AVDL or ALDX? In the previous week, Avadel Pharmaceuticals had 5 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 7 mentions for Avadel Pharmaceuticals and 2 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.75 beat Avadel Pharmaceuticals' score of 0.48 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avadel Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aldeyra Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAvadel Pharmaceuticals beats Aldeyra Therapeutics on 9 of the 14 factors compared between the two stocks. Get Aldeyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALDX vs. The Competition Export to ExcelMetricAldeyra TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$270.73M$2.43B$5.56B$9.04BDividend YieldN/A1.79%5.25%4.03%P/E Ratio-4.959.3827.1820.14Price / SalesN/A765.58440.78137.14Price / CashN/A164.1737.5058.41Price / Book4.034.698.085.60Net Income-$55.85M$31.26M$3.16B$248.43M7 Day Performance11.50%6.81%3.77%5.15%1 Month Performance79.10%4.12%3.90%7.62%1 Year Performance41.18%4.05%34.22%21.56% Aldeyra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALDXAldeyra Therapeutics2.6726 of 5 stars$4.80+6.2%$9.50+97.9%+32.9%$270.73MN/A-4.9510AVDLAvadel Pharmaceuticals2.7046 of 5 stars$8.85-3.8%$18.17+105.3%-39.9%$890M$169.12M-32.7870ARDXArdelyx4.4608 of 5 stars$3.92+6.2%$10.89+177.8%-17.3%$882.85M$333.61M-17.8290Analyst RevisionXERSXeris Biopharma3.1101 of 5 stars$4.67-0.6%$6.25+33.8%+147.2%$735.01M$203.07M0.00290News CoverageCRONCronos Group2.2936 of 5 stars$1.91+0.5%N/A-7.1%$732.80M$117.61M0.00450News CoverageUSNAUSANA Health Sciences3.4893 of 5 stars$30.58-1.8%$36.00+17.7%-23.0%$579.74M$854.50M16.801,700Positive NewsXNCRXencor3.9991 of 5 stars$7.86-3.4%$28.00+256.2%-49.3%$579.33M$110.49M-2.57280KALVKalVista Pharmaceuticals4.1524 of 5 stars$11.31-0.9%$24.83+119.6%+30.2%$567.26MN/A-3.04100Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionRLAYRelay Therapeutics2.5662 of 5 stars$3.46+4.8%$17.67+410.6%-45.1%$565.77M$10.01M0.00330Positive NewsInsider TradeRGLSRegulus Therapeutics1.6373 of 5 stars$8.16flat$8.50+4.2%N/A$564.92MN/A-11.1830AMLXAmylyx Pharmaceuticals3.6762 of 5 stars$6.41+1.3%$11.00+71.6%+338.8%$564.26M$87.37M0.00200News CoverageAnalyst Forecast Related Companies and Tools Related Companies AVDL Competitors ARDX Competitors XERS Competitors CRON Competitors USNA Competitors XNCR Competitors KALV Competitors RLAY Competitors RGLS Competitors AMLX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALDX) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aldeyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
